双特异性抗体治疗晚期B细胞恶性肿瘤的感染预防策略
本文针对接受T细胞衔接双特异性抗体(BsAb)治疗的晚期B细胞恶性肿瘤成人患者,提出基于治疗阶段的感染预防与管理框架。感染是此类患者非复发死亡的主要原因,风险源于B细胞/浆细胞再生障碍、低丙种球蛋白血症、早期血细胞减少及T细胞耗竭等多因素免疫抑制。文章涵盖治疗前评估、治疗期及长期随访,汇总感染筛查、抗菌预防、免疫球蛋白补充和疫苗接种等支持治疗策略。
要点
- BsAb治疗相关感染是nonrelapse mortality主因,需全程动态评估免疫抑制。
- 感染风险机制包括B细胞/浆细胞再生障碍、低丙种球蛋白血症和早期血细胞减少。
- 预防框架分治疗前、治疗期和长期随访三阶段,涵盖筛查、预防和免疫支持。
核心结论
- BsAb治疗晚期B细胞恶性肿瘤时感染常见且是非复发死亡的主要原因,需采用基于治疗阶段的框架进行预防和管理。
研究设计与样本
- 本文为「How I Treat」综述,基于文献和临床经验提出实践框架,未报告系统检索范围或样本量。
主要发现
- 感染风险由多因素动态累积导致,包括B细胞或浆细胞再生障碍、低丙种球蛋白血症、早期血细胞减少、T细胞耗竭、细胞因子导向免疫调节及疾病相关免疫缺陷。
- BsAb相关免疫抑制模式与CAR-T等其他治疗不同,重复给药可导致宿主免疫的动态累积损伤。
关键数值与推荐
- 预防策略涵盖感染病筛查、抗菌药物预防、免疫球蛋白补充、疫苗接种及其他支持治疗,但原文摘要未报告具体阈值、剂量或推荐等级。
临床怎么用
- 临床应将感染预防整合到BsAb治疗全程,包括治疗前评估、治疗期监测和长期随访,并针对B细胞/浆细胞再生障碍及低丙种球蛋白血症等机制采取对应支持措施。
局限性
- 本文为实践框架综述,摘要未报告系统检索方法、证据等级或具体数值,推荐需结合个体情况和本地指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell-engaging bispecific antibodies (BsAbs) have transformed the treatment landscape for multiple hematologic malignancies and are under investigation in the frontline setting, within combination regimens, and for nonmalignant diseases. However, their increasing use has revealed new patterns of immune suppression and infectious complications that differ from other treatment modalities, including chimeric antigen receptor T-cell therapy. Notably, infections are frequent and represent the principal cause of nonrelapse mortality. These risks with repeated BsAb dosing arise from multifactorial mechanisms, including B-cell or plasma-cell aplasia, hypogammaglobulinemia, and early cytopenias. Additional contributors such as T-cell exhaustion, cytokine-directed immune modulation, and disease-related immunodeficiency, further compound infection risk. The result is a dynamic and cumulative impairment of host immunity that evolves over the course of therapy. In this "How I Treat" article, we provide a practical, phase-based framework for preventing and managing infections in patients receiving BsAbs for non-Hodgkin lymphoma or multiple myeloma. Our review includes pretreatment evaluation, the period of active therapy, and long-term follow-up. Using representative cases, we highlight strategies for infectious disease screening, antimicrobial prophylaxis, immunoglobulin supplementation, vaccination, and other supportive care practices. Our aim is to equip clinicians with an evidence-informed and pragmatic framework for mitigating BsAb-related infection risks.
引用
- Rejeski K, Banerjee R, Hill JA, et al. How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies. Blood. 2026. PMID: 42118692. doi:10.1182/blood.2025032298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。